Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

824
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
824
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

257
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
257
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

316
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
316
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

106
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
106
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

163
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
163

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Muscle & nerve·2026
Same author

Primary prevention of Parkinson's disease: proceedings, the 8C's and a position statement from the Parkinson's disease prevention think tank.

NPJ Parkinson's disease·2026
Same author

Healthy Dietary Patterns and Risk of Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

PD GENEration: An International Parkinson's Disease Genetic Research Study.

medRxiv : the preprint server for health sciences·2026
Same author

Exercise and smoking: health rivals revealing shared protective mechanisms in Parkinson's?

NPJ Parkinson's disease·2026

Related Experiment Video

Updated: Dec 12, 2025

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.9K

Does Serum Urate Change as Parkinson's Disease Progresses?

Yasemin G Hasimoglu1, Xiqun Chen1, Rachit Bakshi1

  • 1Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, USA.

Journal of Parkinson'S Disease
|August 11, 2020
PubMed
Summary

Higher serum urate levels may lower Parkinson's disease (PD) risk and slow progression. However, this study found that changes in serum urate did not correlate with PD worsening over five years, suggesting it's not a reliable biomarker for early PD progression.

Keywords:
Parkinson’s diseasedisease progressionlongitudinal studyurate

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.5K

Related Experiment Videos

Last Updated: Dec 12, 2025

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.9K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.5K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Clinical Neurology

Background:

  • Elevated serum urate is linked to reduced Parkinson's disease (PD) risk and slower progression.
  • The association between serum urate levels and PD severity remains incompletely understood.
  • This study explores the longitudinal relationship between serum urate concentration and PD progression markers.

Discussion:

  • Serum urate concentrations remained stable over the 5-year study period.
  • No significant correlation was observed between changes in serum urate and worsening of PD progression metrics.
  • This suggests serum urate may not serve as a dynamic biomarker for monitoring PD advancement in its early stages.

Key Insights:

  • Changes in serum urate concentration over five years did not predict disease progression in Parkinson's patients.
  • MDS-UPDRS Part III scores, Hoehn and Yahr stages, and DaTscan imaging did not correlate with serum urate fluctuations.
  • Serum urate levels appear to be a stable factor, not a responsive biomarker for early Parkinson's disease progression.

Outlook:

  • Further research is needed to explore the role of serum urate in different stages of Parkinson's disease.
  • Investigating other potential biomarkers for monitoring PD progression is crucial.
  • Understanding the complex interplay between urate metabolism and neurodegeneration may offer future therapeutic targets.